Overview

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

Status:
NOT_YET_RECRUITING

Trial end date:
2028-10-30

Target enrollment:

Participant gender:

Summary

This single-center, prospective study and aims to evaluate the efficacy and safety of limertinib combined with etoposide and carboplatin in EGFR-mutant NSCLC patients who develop small-cell lung cancer transformation following progression on EGFR-TKI therapy.

Phase:

PHASE2

Details

Lead Sponsor:

Hunan Province Tumor Hospital

Treatments:

Carboplatin
Etoposide